Clinical trials for Pancreas cancer

154 currently recruiting clinical trials
Phase 1 / Phase 2 Pancreas cancer #NCT05706129 #2023-504254-35-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2 Pancreas cancer #NCT06885034 #2025-520672-26-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer #NCT06162221
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Revolution Medicines, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT06781983
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Innate Pharma
Phase 1 Pancreas cancer #NCT04939610 #2023-508995-12-01
PDAC Combinaison
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis
Phase 1 Breast cancer Lung cancer Pancreas cancer Lymphoma CLL & Richter's syndrome Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST #NCT06823167 #2025-523160-20-00
Partie A
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Mesothelium B cell lymphoma Richter's syndrome Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC) Soft tissue sarcoma
Required histologic sub types
Non-squamous NSCLC Large B cell lymphoma Mantel cell lymphoma Follicular lymphoma Lymphocytic lymphoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Immunome, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Lymphoma Ovarian / Fallopian tubes / Peritoneum cancer #NCT06514651 #2023-507774-41-00
Required disease stage
Metastatic
Required number of previous lines of therapy
1 2 3 or more
1 recruiting site
MabQuest SA
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06507306 #2024-511453-22-00
Partie 1Escalade de dose monothérapie
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other KRAS EGFR KRAS G12C KRAS G12D KRAS non G12C NRAS Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Kumquat Biosciences Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT06253871 #2024-519188-17-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Iambic Therapeutics, Inc
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04777994 #2023-507568-38-00
Escalade de dose (Tumeurs solides)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Calico Life Sciences LLC